Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.10.18
Views: 536

Dr Roy S. Herbst - Yale Cancer Centre, New Haven, USA

Dr Roy S. Herbst talks to ecancer at ESMO 2018 about the latest from the KEYNOTE-10 trial for non small cell lung cancer.

He discussed the latest data from this trial, noting the improved 3 year survival rate with patients expressing higher levels of PD-L1.

Among patients who relapsed, he also reports responses among those retreated with pembrolizumab, and considers what it may mean for treatment options in the refractory setting.

For more lung cancer news, watch Dr Enriqueta Felip summarise lung highlights from ESMO 2018 here.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG e-learning July 2017

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation